Kiniksa Pharmaceuticals International (KNSA) recently reported first quarter 2026 results, with revenue of US$214.27 million and net income of US$22.59 million, and raised its full year net product revenue guidance.
See our latest analysis for Kiniksa Pharmaceuticals International.
The share price has responded strongly to the Q1 2026 results and higher net product revenue guidance, with a 7 day share price return of 32.13% adding to a 37.17% year to date share price return and a 1 year total shareholder return of 107.42%. This suggests that momentum has been building as investors reassess growth prospects and risk.
If Kiniksa’s recent move has you looking for more healthcare opportunities tied to new therapies, it could be a good moment to scan 33 healthcare AI stocks
With Kiniksa now trading at US$57.62 and sitting only around 10% below the average analyst price target, the key question is whether recent momentum leaves more room for additional gains or if the market is already pricing in expectations for future growth.
Most Popular Narrative: 3.1% Overvalued
The most followed narrative pegs Kiniksa’s fair value at $55.88, slightly below the last close at $57.62, so the story leans toward modest overvaluation today.
The analyst price target for Kiniksa Pharmaceuticals International has edged up from $55 to about $55.88. Analysts point to the company's Arcalyst franchise, recent coverage initiations, and the size of the recurrent pericarditis treatment market as key supports for their updated view.
Want to see what is baked into that fair value? The narrative leans on rapid earnings expansion, rising margins, and a rich future earnings multiple. The exact mix may surprise you.
Result: Fair Value of $55.88 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to factor in Kiniksa’s heavy reliance on Arcalyst, as well as the risk that new competitors or pricing pressure could unsettle the current narrative.
Find out about the key risks to this Kiniksa Pharmaceuticals International narrative.
Another View: Cash Flows Paint a Very Different Picture
While the popular narrative points to Kiniksa as about 3.1% overvalued at a fair value of $55.88, the SWS DCF model lands in a very different place. On that approach, the stock is trading roughly 71.2% below an estimated future cash flow value of $200.22, which implies a wide gap between earnings based expectations and long term cash flow assumptions. For you, the real question is which story feels more realistic.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kiniksa Pharmaceuticals International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The mix of enthusiasm and caution around Kiniksa might feel conflicting, so treat this as a prompt to review the data quickly and form your own stance. After that, take a closer look at the 3 key rewards
Ready to find more investment ideas?
If Kiniksa has sharpened your focus, do not stop here. Use this moment to refresh your watchlist with other stocks that match the kind of profile you want.
- Target resilience by checking companies on the 70 resilient stocks with low risk scores that may better match your tolerance for volatility.
- Hunt for quality at a sensible price with the 48 high quality undervalued stocks and see which stocks line up with your return expectations.
- Build a shortlist of potential income plays using the 12 dividend fortresses and avoid missing dividend opportunities that fit your style.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com